Statins and the skin: systematic review of dermatologic reactions to statin therapy

Rebecca Fliorent; Alexandra Gershman; Mariam Tinawi; Hannah  Kopelman; Panagiotis  Mitropoulos

doi:10.18203/issn.2455-4529.IntJResDermatol20263744

Authors

Rebecca Fliorent Weill Cornell Medicine Department of Pathology and Laboratory Medicine, NY, United States https://orcid.org/0009-0003-5934-8896
Alexandra Gershman Touro College of Osteopathic Medicine Middletown, NY, United States https://orcid.org/0009-0001-8507-3158
Mariam Tinawi Rowan University School of Osteopathic Medicine, Stratford, NJ, United States
Hannah Kopelman Department of Dermatology, Kansas City University-GME Consortium/Advanced Dermatology and Cosmetic Surgery, Orlando, FL, United States https://orcid.org/0000-0002-7141-9947
Panagiotis Mitropoulos Department of Dermatology, Kansas City University-GME Consortium/Advanced Dermatology and Cosmetic Surgery, Orlando, FL, United States https://orcid.org/0000-0002-6450-2670

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20263744

Keywords:

Cutaneous adverse drug reactions, Lichenoid drug eruption, Dermatomyositis, Statins

Abstract

Statins are widely prescribed medications for lowering cholesterol levels. While generally well-tolerated, they can cause various cutaneous adverse reactions through disruption of the mevalonate pathway, affecting immune cell function and potentially triggering autoimmune responses. Aim was to systematically evaluate the clinical and histopathologic features of statin-associated cutaneous adverse reactions and review reported management strategies. A systematic review following PRISMA guidelines using PubMed, Embase, and Scopus databases was conducted analyzing cutaneous adverse reactions associated with statin therapy, including clinical presentation, histopathologic features, and management strategies. Inclusion criteria encompassed case reports, randomized controlled trials, and observational studies investigating statin-induced cutaneous adverse effects in human subjects. Studies were excluded if they were animal trials, systematic reviews, literature reviews, or did not focus on statin-related cutaneous reactions. The 22 published cases were identified, affecting patients with a mean age of 61 years (range: 44-84) and slight female predominance. The most frequently reported reactions were eczematous eruptions (6 cases), lichenoid drug eruptions (4 cases), dermatomyositis (DM) (4 cases), and pityriasis lichenoides chronica (PLC) (3 cases). Additional manifestations included lupus erythematosus tumidus (LET), pemphigus erythematosus, erythema multiforme, fixed drug eruption, and thrombocytopenic purpura. Histopathologic features commonly showed immune-mediated patterns including interface dermatitis, basal vacuolar changes, and lymphocytic infiltrates. Most cases resolved following statin discontinuation, though some required adjunctive corticosteroids or immunosuppressive therapy. This review adds to the body of literature by highlighting the breadth of statin-associated cutaneous adverse effects, emphasizing the need for clinicians to maintain a high index of suspicion when evaluating new skin eruptions in patients on statin therapy. Prompt identification and tailored management can lead to improved patient outcomes and medication safety.

Metrics

Metrics Loading ...

References

Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-13. DOI: https://doi.org/10.1161/01.CIR.101.2.207

Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11. DOI: https://doi.org/10.1016/j.phrs.2014.03.002

Navarro-Triviño FJ, Ruiz-Villaverde R. Lichenoid drug eruption induced by pravastatin; it is possible to prescribe other statins? An Bras Dermatol. 2023;98(1):116-7. DOI: https://doi.org/10.1016/j.abd.2021.02.013

Oztas M, Ugurlu S, Aydin O. Atorvastatin-induced dermatomyositis. Rheumatol Int. 2017;37(7):1217-9. DOI: https://doi.org/10.1007/s00296-017-3658-9

Chacko AM, Carrero G, Akhouri S. A Case Report of Erythema Multiforme Secondary to Atorvastatin Use. Cureus. 2024;16(1):e52175. DOI: https://doi.org/10.7759/cureus.52175

Lagunas-Rangel FA, Liepinsh E, Fredriksson R. Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases. Br J Pharmacol. 2024;181(20):3799-818. DOI: https://doi.org/10.1111/bph.17309

Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol. 2004;13(6):337-9. DOI: https://doi.org/10.1111/j.0906-6705.2004.00208.x

Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17-24. DOI: https://doi.org/10.1111/j.1468-3083.2006.01838.x

Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186(4):248-52. DOI: https://doi.org/10.1159/000247363

Salna MP, Singer HM, Dana AN. Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. Case Rep Dermatol Med. 2017;2017:3418204. DOI: https://doi.org/10.1155/2017/3418204

Roger D, Rolle F, Labrousse F, Brosset A, Bonnetblanc JM. Simvastatin-induced lichenoid drug eruption. Clin Exp Dermatol. 1994;19(1):88-9. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01128.x

Keough GC, Richardson TT, Grabski WJ. Pravastatin-induced lichenoid drug eruption. Cutis. 1998;61(2):98-100.

Sebök B, Tóth M, Anga B, Harangi F, Schneider I. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin). Acta Derm Venereol. 2004;84(3):229-30. DOI: https://doi.org/10.1080/00015550310006851

Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol. 2006;47(1):57-9. DOI: https://doi.org/10.1111/j.1440-0960.2006.00225.x

Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events. Cureus. 2020;12(3):e7155. DOI: https://doi.org/10.7759/cureus.7155

Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110(8):670-1. DOI: https://doi.org/10.1016/S0002-9343(01)00711-2

Spiro J, Butts M. Atorvastatin-Induced Dermatomyositis: Resolution with Change in Statin? J Clin Rheumatol. 2018;24(7):406-409. DOI: https://doi.org/10.1097/RHU.0000000000000709

Gutierrez E, Faraji M, Pacheco L. Weak Knees: A Case of Atorvastatin-induced Dermatomyositis. Cureus. 2020;12(3):e7387. DOI: https://doi.org/10.7759/cureus.7387

Massay RJ, Maynard AA. Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors. West Indian Med J. 2012;61(7):743-5.

Hanson K, Mattes RG, Cauthon KAB. Drug Eruption from Atorvastatin: With Initial Misdiagnosis of Tinea Cruris. Sr Care Pharm. 2023;38(2):63-9. DOI: https://doi.org/10.4140/TCP.n.2023.63

Huertas AJ, Ramírez-Hernández M, Mérida-Fernández C, Chica-Marchal A, Pajarón-Fernández MJ, Carreño-Rojo A. Fixed drug eruption due to atorvastatin. J Investig Allergol Clin Immunol. 2015;25(2):155-6.

Adams AE, Bobrove AM, Gilliam AC. Statins and "chameleon-like" cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg. 2010;14(5):207-11. DOI: https://doi.org/10.2310/7750.2010.09042

Wong ITY, Huang Y, Zhou Y. Drug Eruption to Rosuvastatin with Recurrence on Simvastatin: A Case Report. J Cutan Med Surg. 2018;22(3):359-61. DOI: https://doi.org/10.1177/1203475418756376

Walder A, Baumann P. Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions? Acta Medica (Hradec Kralove). 2009;52(1):15-8. DOI: https://doi.org/10.14712/18059694.2016.101

Possamai G, Bovo P, Santonastaso M. Thrombocytopenic purpura during therapy with simvastatin. Haematologica. 1992;77(4):357-8.

Lo Schiavo A, Puca RV, Romano F, Cozzi R. Pemphigus erythematosus relapse associated with atorvastatin intake. Drug Des Devel Ther. 2014;8:1463-5. DOI: https://doi.org/10.2147/DDDT.S66666

Trčko K, Lukinovič N, Luzar B. Atorvastatin-induced Lupus Erythematosus Tumidus: A Case Report and Literature Review. Acta Dermatovenerol Croat. 2023;31(3):125-32.

Lakey WC, Greyshock NG, Kelley CE. Statin intolerance in a referral lipid clinic. J Clin Lipidol. 2016;10(4):870-9.e3. DOI: https://doi.org/10.1016/j.jacl.2016.03.004